ArticleBMC infectious diseases2026
Trends and determinants of tuberculosis treatment outcomes among patients at Hargeisa tuberculosis hospital, Somaliland (2019-2024): a multi-year retrospective study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a major public health concern in Somaliland, and evidence on multi-year treatment outcomes is limited. This study assessed temporal trends and factors associated with TB treatment outcomes among patients managed at Hargeisa TB Hospital, Somaliland.
methodsWe conducted a register-based retrospective cohort study using routinely collected data from the Hargeisa TB Hospital treatment registers for patients initiating anti-TB treatment from 2019 to 2024. TB treatment outcomes were dichotomised as successful (cured or treatment completed) versus unsuccessful (death, loss to follow-up, treatment failure). Descriptive analyses were performed to present patient characteristics, while bivariate and multivariate logistic regression models were used to identify variables linked to treatment success. Adjusted odds ratios (AORs) with 95% confidence intervals (CIs) were calculated, and a p-value of less than 0.05 was considered statistically significant.
resultsAcross the six-year period, treatment success rates remained above 85%. Significant predictors of treatment outcomes varied by year. Between 2020 and 2024, age consistently predicted outcomes, with patients aged ≥ 55 years significantly less likely to achieve successful treatment (AOR range: 0.24-0.44). HIV-negative patients had up to fourfold higher odds of treatment success (AOR = 4.30; 95% CI: 1.76-10.49; p = 0.001).
conclusionTB treatment success consistently met or exceeded the World Health Organization benchmark of ≥ 85% across all study years. However, older age and TB/HIV co-infection remained associated with reduced treatment success even after stratification by TB type. These findings highlight the need to strengthen TB/HIV service integration and to provide enhanced clinical management and adherence support for older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.